Results 161 to 170 of about 2,201,777 (199)

Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1. [PDF]

Cancer Sci
Men B, Chen Z, Ge H, Yang Z, Yun L, Jiang J, Dian M, He Y, Zhou Z, Zhang R, Yan T, Li Z, Zhang Y, He Y, He J, Rao X, Rao S.   +16 more
europepmc   +1 more source

Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors. [PDF]

Cancer Sci
Miyashita Y, Tajima K, Izumi K, Matsumoto N, Hayakawa D, Nakamura IT, Katayama I, Wibowo A, Matsuda H, Winardi W, Amien BR, Mitsuishi Y, Takahashi F, Nakamura K, Uchibori K, Yanagitani N, Hayashi T, Takamochi K, Suzuki K, Katayama R, Takahashi K.   +20 more
europepmc   +1 more source

A Hybrid Protein-Oxygen Nanomedicine Overcomes Osimertinib Resistance in NSCLC via HIF-1α/VEGF/EGFR Inhibition. [PDF]

Int J Nanomedicine
Jiang G, Liu X, Zhang D, Diao Z, Yang X, Tan Q, Chen S, Zhang W, Yin X, Yin T, Wang X, Zhou J.   +11 more
europepmc   +1 more source

Targeting RRM2 with dual-modal theranostic smart nanoresponder overcomes osimertinib resistance and triggers immune remodeling in NSCLC. [PDF]

Sci Adv
Zhu J, Cui K, Zhou W, Zhou X, Yao Y, Zhao C, Yang Y, Liu Y, Tao J, Yang Z, Zhu H, Tang B, Li N.   +12 more
europepmc   +1 more source

Correction to "Trametinib Overcomes KRAS-G12V-Induced Osimertinib Resistance in a Leptomeningeal Carcinomatosis Model of EGFR-Mutant Lung Cancer". [PDF]

Cancer Sci
europepmc   +1 more source

Prolonged complete metabolic response to chemotherapy combined with amivantamab with high grade cutaneous toxicity after osimertinib resistance in an uncommon <i>T751_I759delinsAsp</i> <i>EGFR</i>-mutant lung adenocarcinoma: a case report. [PDF]

Transl Lung Cancer Res
Barbe-Richaud JB, Pencreach E, Schott R, Holder E, Somme L.   +4 more
europepmc   +1 more source

A novel biguanide-derivative promotes NEDD4-mediated FGFR1 ubiquitination through BMI1 to overcome osimertinib resistance in NSCLC. [PDF]

Cancer Biol Med
Peng M, Wang W, Xiao D, Li D, Deng J, Zou H, Feng X, Yang Y, Fan S, Yang X.   +9 more
europepmc   +1 more source

STAT3 mediates CAF-induced osimertinib resistance via regulating protein secretion in non-small cell lung cancer. [PDF]

Front Pharmacol
Fan X, Wu S, Wu H, Huang Y, Tong X, Yu M, Liu Z.   +6 more
europepmc   +1 more source

Osimertinib resistance-based immune prognostic related gene signature in EGFR mutant lung adenocarcinoma, in which PSMD11 promotes tumor progression. [PDF]

Transl Lung Cancer Res
Bai Y, Xu H, Bao P, Gao Y, Sun J, Shen Y, Zhao J, Jiang T.   +7 more
europepmc   +1 more source

Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options

Cancers, 2023
The development of tyrosine kinase inhibitors (TKIs) targeting the mutant epidermal growth factor receptor (EGFR) protein initiated the success story of targeted therapies in non-small-cell lung cancer (NSCLC).
Nick Syrigos, Georgia Gomatou, Elias Kotteas   +2 more
exaly   +4 more sources